News
Press Releases
Amylon appoints Art Levin to supervisory board; expands scientific advisory board
Cambridge, Massachusetts, January 17 2019
Amylon Therapeutics, a biotechnology company using RNA modulation to target neurological disorders, announces the appointment of Art Levin as its new supervisory board member, as well as the expansion of its scientific advisory board with the appointment of Benny Sorensen and Matthew During.
Dan Curtis joins Amylon Therapeutics as Chief Development Officer
Cambridge, Massachusetts, June 26 2018
Amylon Therapeutics, a biotechnology company using an ultragenetics approach towards neurological disorders, announces the appointment of Daniel Curtis PhD as its new Chief Development Officer. In his role, Dan will be responsible for driving the company’s lead program AT-010 forward, expanding the pipeline, and overseeing all R&D activities.
Amylon Therapeutics and Alcyone Lifesciences enter into partnership on drug-device combo to treat HCHWA-D
Cambridge, Massachusetts, April 5 2018
Amylon Therapeutics, a biotechnology company using an ultra-genetics approach towards neurological disorders, and Alcyone Lifesciences, a leader in precision advanced central nervous system (CNS) delivery systems, announce that they have entered into a collaboration partnership agreement.
Dr. Bo Jesper Hansen joins supervisory board Amylon Therapeutics
Leiden, the Netherlands, February 21 2018
Amylon Therapeutics, a biotechnology company using an ultra-genetic approach towards neurological disorders, announces the appointment of Bo Jesper Hansen MD, PhD, as its new supervisory board member and investor. Dr. Hansen brings with him a wealth of experience from his extensive career in orphan drug development and numerous supervisory board roles.
Amylon Therapeutics Targeting central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe® Berlin
Berlin, Germany, November 8 2017
Amylon Therapeutics was today announced as the winner of the Startup Slam competition at this year’s BIO-Europe® 2017 annual conference in Berlin. Thomas de Vlaam, CEO and founder of Amylon Therapeutics, will receive a complimentary registration to BIO-Europe® Spring 2018 from EBD Group and the opportunity to enter a year-long no fee arrangement to become a Johnson & Johnson Innovation, JLINX community member.
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
Leiden, the Netherlands, September 12 2017
ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced that the company has spun out Amylon Therapeutics (Amylon), a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders.
Amylon Therapeutics rondt eerste fase startkapitaal af, Focus op aandoeningen van het centraal zenuwstelsel.
Leiden, Nederland, September 12 2017
Amylon Therapeutics B.V., een spin-off bedrijf van ProQR Therapeutics, kondigt vandaag de succesvolle afsluiting van zijn eerste investeringsronde aan. De startkapitaal financiering werd verzorgd door een consortium van private en institutionele investeerders. ProQR wordt meerderheidsaandeelhouder. Amylon Therapeutics richt zich op aandoeningen van het centraal zenuwstelsel (CNS) door middel van een ultra-genetics benadering, met de focus op zeldzame genetische ziektes die kunnen dienen als een mogelijke springplank naar vaker voorkomende aandoeningen.
Amylon Therapeutics announces seed investment round
Leiden, the Netherlands, September 12 2017
Amylon Therapeutics B.V., a spin-off company of ProQR Therapeutics, today announced the closure of its first investment round. The seed round was provided by a consortium of private and institutional investors. ProQR becomes a majority shareholder. Amylon Therapeutics targets Central Nervous System (CNS) disorders through an ultra-genetics approach, focusing on rare genetic disorders that can serve as a possible gateway to global indications.